Spero Therapeutics, Inc. (SPRO)
1.21
-0.01
(-0.82%)
USD |
NASDAQ |
Aug 24, 16:00
1.21
0.00 (0.00%)
After-Hours: 20:00
Spero Therapeutics Shareholders Equity (Quarterly) : 44.20M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 44.20M |
| March 31, 2026 | 52.93M |
| December 31, 2025 | 59.02M |
| September 30, 2025 | 26.49M |
| June 30, 2025 | 32.83M |
| March 31, 2025 | 33.81M |
| December 31, 2024 | 46.12M |
| September 30, 2024 | 65.51M |
| June 30, 2024 | 80.50M |
| March 31, 2024 | 96.25M |
| December 31, 2023 | 106.89M |
| September 30, 2023 | 53.70M |
| June 30, 2023 | 54.78M |
| March 31, 2023 | 64.84M |
| December 31, 2022 | 75.93M |
| September 30, 2022 | 32.48M |
| June 30, 2022 | 35.92M |
| March 31, 2022 | 62.47M |
| Date | Value |
|---|---|
| December 31, 2021 | 88.29M |
| September 30, 2021 | 111.90M |
| June 30, 2021 | 90.25M |
| March 31, 2021 | 118.85M |
| December 31, 2020 | 132.04M |
| September 30, 2020 | 132.79M |
| June 30, 2020 | 73.71M |
| March 31, 2020 | 82.43M |
| December 31, 2019 | 74.57M |
| September 30, 2019 | 92.68M |
| June 30, 2019 | 109.31M |
| March 31, 2019 | 112.97M |
| December 31, 2018 | 115.50M |
| September 30, 2018 | 125.20M |
| June 30, 2018 | 65.31M |
| March 31, 2018 | 74.54M |
| December 31, 2017 | 84.60M |
| September 30, 2017 | 23.92M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Inovio Pharmaceuticals, Inc. | 4.371M |
| Fortress Biotech, Inc. | 164.14M |
| Kura Oncology, Inc. | 48.43M |
| Legend Biotech Corp. | 1.230B |
| ACADIA Pharmaceuticals, Inc. | 1.307B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 52.77M |
| Total Liabilities (Quarterly) | 8.562M |
| Debt to Equity Ratio | 0.0462 |
| Current Ratio | 6.121 |
| Net Debt Paydown Yield | 0.30% |